UPPSALA, Sweden, June 13, 2002 (PRIMEZONE) -- Pyrosequencing AB (Stockholm: PYRO A) today announced the worldwide launch of the Pyrosequencing(TM) Vacuum Prep Tool - the new time and labor efficient device that accurately prepares DNA samples for genetic analysis by the PSQ(TM)HS 96A System. This hand-held tool uses the speed of vacuum filtration to batch process 96 samples in a straightforward procedure that takes less than 15 minutes to perform. Speed and simplicity are further enhanced by the ergonomic bench-top workflow created by minimal pipetting and an intuitive operating procedure. The filter probes within the tool are designed for repeated use, with each set able to prepare over 50 96-well plates.
"Sample preparation for genetic analysis is often a rate-limiting step to significantly increasing throughput," said Marten Winge, Vice President Worldwide Marketing, Sales and Support. "This new companion product to the PSQ HS 96A System gives our customers what they need to prepare more samples faster and with less effort. We continue to examine innovative solutions to enhance Applied Genetic Analysis and have begun to transform several of these into products."
During 2002, Pyrosequencing expanded its product portfolio with the introduction of two new genetic analysis solutions - the PSQ HS 96A and PSQ(TM)96MA Systems. The PSQ HS 96A System is a medium to high- throughput, dedicated SNP and mutation analysis system that delivers cost efficient analysis and hours of unattended operation. The PSQ 96MA System is a multi-application solution, ideally suited for a broad range of applications within Applied Genomics. Pyrosequencing also provides high-throughput genotyping solutions with a 384-well format, currently available through an early access Preferred Technology Program (PTP(TM)).
About Pyrosequencing AB
Pyrosequencing AB develops, manufactures and sells complete solutions for rapid applied genetic analysis based on its proprietary Pyrosequencing(TM) technology, a simple-to-use DNA sequencing technique. Pyrosequencing leads the global market in Applied Genomics with over 165 systems sold to major pharmaceutical and biotech companies and prestigious research institutions worldwide.
Pyrosequencing(TM) technology is broadly applicable for the analysis of single nucleotide polymorphisms (SNPs) and for the identification and quantification of short DNA sequences used in bacterial and viral typing. The Company's Molecular Diagnostics Business is establishing collaborations with industry leaders to identify new product opportunities in disease diagnosis, clinical prognosis and pharmacogenomics.
The Company's products include the bench-top PSQ(TM)96, PSQ(TM)96MA and PSQ(TM)HS 96A Systems and a high-throughput PTP(TM) System, all of which utilize proprietary software and reagent kits. Among Pyrosequencing's customers are AstraZeneca, GlaxoSmithKline, Merck, Schering-Plough, the NIH, the Harvard Center for Cancer Prevention, Yale University, the Karolinska Institute, Biogen, Oxagen, Ltd., NASA and DuPont Agriculture. The Company's Web address is www.pyrosequencing.com.
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," and "anticipate," among others. These forward- looking statements are based on Pyrosequencing's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Pyrosequencing notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward- looking statements. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing and genomics market, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Pyrosequencing's products (including seasonal fluctuations), difficulties in successfully adapting the Company's products to integrated solutions and producing such products, and the Company's ability to identify and develop new products and to differentiate its products from competitors.
FOR FURTHER INFORMATION CONTACT:
Pyrosequencing AB Erik Wallden President and CEO erik.wallden@pyrosequencing.com Phone: +46 18 56 59 02 or +46 70 326 98 70 Theresa McNeely, Sr. Director Investor and Public Relations theresa.mcneely@pyrosequencing.com Phone: +1 877 797 6767 Marten Winge Vice President Worldwide Marketing, Sales and Support marten.winge@pyrosequencing.com Phone: +46 18 56 59 27
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
www.waymaker.net/bitonline/2002/06/13/20020613BIT00770/wkr0001.doc www.waymaker.net/bitonline/2002/06/13/20020613BIT00770/wkr0002.pdf